Reliance Industries backed Strand Life Sciences has secured an Indian patent for an artificial intelligence based technology designed to improve the detection and classification of blood cancers, marking a significant milestone in the use of AI for precision diagnostics and personalised healthcare.
The patent covers an AI driven computational method that analyses complex genomic data to identify and classify different forms of blood cancer with greater speed and accuracy. The company said the innovation is expected to support clinicians by providing advanced molecular insights that can improve diagnosis and treatment planning.
Blood cancers, including leukemia, lymphoma and multiple myeloma, often require extensive laboratory testing and genomic analysis before a definitive diagnosis can be made. The newly patented AI system is designed to process large genomic datasets and identify disease specific biomarkers that may not be immediately apparent through conventional analysis.
According to Strand Life Sciences, the technology combines artificial intelligence with bioinformatics to interpret sequencing data more efficiently, enabling healthcare professionals to make informed clinical decisions. The platform is intended to complement existing diagnostic workflows rather than replace laboratory testing, offering an additional layer of precision in identifying cancer subtypes.
The patent represents another step in the growing application of AI across healthcare diagnostics. Artificial intelligence is increasingly being deployed to analyse medical images, genomic information, pathology data and clinical records, helping physicians detect diseases earlier while improving diagnostic consistency and operational efficiency.
Industry experts note that AI is particularly valuable in genomics because of the enormous volume and complexity of sequencing data generated during cancer testing. Machine learning models can rapidly identify patterns across millions of genetic data points, enabling researchers and clinicians to uncover disease signatures that would otherwise require extensive manual analysis.
Strand Life Sciences has been active in genomic research, precision medicine and molecular diagnostics for more than two decades. Following its acquisition by Reliance Industries in 2021, the company has expanded investments in genomics, bioinformatics and AI powered healthcare technologies, aligning with Reliance's broader ambitions in digital health and advanced life sciences.
The newly granted patent further strengthens the company's intellectual property portfolio in computational biology and AI assisted diagnostics. While the company has not announced a commercial rollout timeline, the patented technology is expected to support future diagnostic products focused on oncology and precision medicine.
Healthcare providers worldwide are increasingly adopting AI driven diagnostic tools as demand grows for faster and more accurate disease detection. Advances in sequencing technologies have generated vast quantities of genomic information, creating opportunities for AI systems to improve interpretation and reduce the time required for clinical analysis.
The development also reflects the broader convergence of artificial intelligence and biotechnology. Pharmaceutical companies, research institutions and healthcare organisations are investing heavily in AI platforms that can accelerate drug discovery, improve disease prediction and enable more personalised treatment strategies based on individual genetic profiles.
India's healthcare technology ecosystem has witnessed growing momentum in AI based medical innovation, supported by increased investments in genomics, digital health infrastructure and medical research. Companies are exploring AI applications across oncology, radiology, pathology, ophthalmology and preventive healthcare to improve patient outcomes and expand access to advanced diagnostics.
For patients, earlier and more precise identification of blood cancers can significantly influence treatment decisions and long term clinical outcomes. AI powered genomic analysis has the potential to reduce diagnostic delays while supporting clinicians with more detailed molecular information during disease evaluation.
Reliance backed Strand Life Sciences' latest patent underscores the increasing role of artificial intelligence in transforming healthcare diagnostics. As AI continues to mature alongside advances in genomic medicine, technologies that combine machine learning with molecular analysis are expected to play a growing role in enabling faster, more personalised and data driven healthcare delivery.